Aravive (NASDAQ:ARAV – Get Rating) had its target price hoisted by HC Wainwright from $7.00 to $12.00 in a report issued on Wednesday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Aravive’s FY2027 earnings at $0.78 EPS.
Separately, EF Hutton Acquisition Co. I reaffirmed a buy rating and set a $10.00 price target on shares of Aravive in a report on Tuesday, February 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Aravive presently has a consensus rating of Buy and a consensus price target of $9.20.
Aravive Price Performance
ARAV stock opened at $1.96 on Wednesday. The business has a fifty day moving average price of $1.84 and a 200 day moving average price of $1.41. Aravive has a fifty-two week low of $0.58 and a fifty-two week high of $2.23. The stock has a market capitalization of $117.27 million, a price-to-earnings ratio of -0.89 and a beta of 2.35.
Institutional Investors Weigh In On Aravive
Aravive, Inc operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression.
- Get a free copy of the StockNews.com research report on Aravive (ARAV)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.